Roche Holding stock faces CTAD focus after new Alzheimer plans
Published on 11/10/2026 at 11:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAlzheimer pipeline takes center stage
- Roche is expanding its Alzheimer strategy beyond amyloid clearance with a new neuroinflammation study.
- Investors will receive updated clinical and diagnostic information at the CTAD congress in Boston.
- The program links investigational medicines with blood-based testing across the disease pathway.
Roche announced on Tuesday, November 10, that it will present new pharmaceutical and diagnostic data at the Clinical Trials on Alzheimer's Disease congress in Boston from November 16 to 19. The company also said it is starting TARBELA-AD, a Phase II trial of the oral NLRP3 inhibitor RG6434 in people with early symptomatic Alzheimer's disease. The details were published in a Roche release carried by Press Release Feed.
New trial broadens Alzheimer strategy
The TARBELA-AD study adds a neuroinflammation approach to Roche's existing work on amyloid biology. The company is continuing programs for trontinemab, its investigational Brainshuttle antibody, while using RG6434 to test another biological mechanism that may contribute to disease progression.
Roche said the CTAD program will include updated Phase Ib/IIa Brainshuttle AD results for trontinemab, including findings on amyloid removal dynamics and biomarkers. The company will also present the design of the Phase III PrevenTRON study in preclinical Alzheimer's disease, which has begun enrolling participants.
Diagnostics remain part of strategy
The presentations will also cover Roche's Elecsys pTau217 and pTau181 blood tests. Roche said the portfolio is intended to support earlier and more accessible assessment of Alzheimer's pathology in both specialist and primary-care settings. The company describes pTau217 as an FDA-cleared blood test that can rule in and rule out amyloid pathology.
Roche plans 16 accepted abstracts at CTAD, including two scientific symposia and two oral presentations. Topics include trontinemab's brain delivery, the rationale for NLRP3 inhibition, the PrevenTRON study design and health-economic evidence for blood-based biomarkers.
Upcoming investor milestones
Roche's investor calendar lists appearances at the UBS European Conference in London and the UBS Global Healthcare Conference in Palm Beach on November 10. The CTAD presentations provide the next scheduled scientific milestone for the Alzheimer portfolio and could give investors more detail on study design, biomarker development and the timing of future data.
Roche Holding stock traded at 434.50 euros on Lang & Schwarz at 11:16:58 CET on Tuesday, November 10, 2026.
Roche Holding at a glance
- Company: Roche Holding AG
- ISIN: CH1499059983
- Trading venue: Lang & Schwarz
- Price: 434.50 euros at 11:16:58 CET on November 10, 2026
- Next scientific event: CTAD congress, November 16-19, 2026
Swiss healthcare shares remain linked to the wider market through the SMI market environment.
More news and analyses on Roche Holding stock.
